These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10328537)

  • 1. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA.
    Giraud A; Ataman-Onal Y; Battail N; Piga N; Brand D; Mandrand B; Verrier B
    J Virol Methods; 1999 Apr; 79(1):75-84. PubMed ID: 10328537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles.
    Brand D; Lemiale F; Turbica I; Buzelay L; Brunet S; Barin F
    AIDS Res Hum Retroviruses; 1998 Oct; 14(15):1369-77. PubMed ID: 9788678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice.
    Ajbani SP; Velhal SM; Kadam RB; Patel VV; Bandivdekar AH
    Int J Biol Macromol; 2015 Nov; 81():794-802. PubMed ID: 26361864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.
    Paul NL; Marsh M; McKeating JA; Schulz TF; Liljeström P; Garoff H; Weiss RA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):963-70. PubMed ID: 8280479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
    Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
    Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.
    Berglund P; Quesada-Rolander M; Putkonen P; Biberfeld G; Thorstensson R; Liljeström P
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1487-95. PubMed ID: 9390747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model.
    Notka F; Stahl-Hennig C; Dittmer U; Wolf H; Wagner R
    Biol Chem; 1999 Mar; 380(3):341-52. PubMed ID: 10223337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
    Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F
    Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
    Chakrabarti BK; Kong WP; Wu BY; Yang ZY; Friborg J; Ling X; King SR; Montefiori DC; Nabel GJ
    J Virol; 2002 Jun; 76(11):5357-68. PubMed ID: 11991964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
    Moore PL; Crooks ET; Porter L; Zhu P; Cayanan CS; Grise H; Corcoran P; Zwick MB; Franti M; Morris L; Roux KH; Burton DR; Binley JM
    J Virol; 2006 Mar; 80(5):2515-28. PubMed ID: 16474158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with HIV-1 subtype B gp160-DNA induces specific as well as cross reactive immune responses in mice.
    Arora A; Seth P
    Indian J Med Res; 2001 Jul; 114():1-9. PubMed ID: 11762199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120.
    Altmeyer R; Escriou N; Girard M; Palmenberg A; van der Werf S
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9775-9. PubMed ID: 7937890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.
    Lewis AD; Chen R; Montefiori DC; Johnson PR; Clark KR
    J Virol; 2002 Sep; 76(17):8769-75. PubMed ID: 12163597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches.
    Lemiale F; Brand D; Lebigot S; Verrier B; Buzelay L; Brunet S; Barin F
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):413-22. PubMed ID: 11391160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of monoclonal antibodies to human immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli.
    Larcher C; Bröker M; Huemer HP; Sölder B; Schulz TF; Hofbauer JM; Wachter H; Dierich MP
    FEMS Microbiol Immunol; 1990 Sep; 2(2):103-10. PubMed ID: 1701654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.
    Pincus SH; Song K; Maresh GA; Hamer DH; Dimitrov DS; Chen W; Zhang MY; Ghetie VF; Chan-Hui PY; Robinson JE; Vitetta ES
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
    Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
    Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.
    Forsell MN; Li Y; Sundbäck M; Svehla K; Liljeström P; Mascola JR; Wyatt R; Karlsson Hedestam GB
    J Virol; 2005 Sep; 79(17):10902-14. PubMed ID: 16103142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.